Along with this, all HF patients were treated with SGLT2 inhibitors and the majority of them received any blocker of the renin–angiotensin–aldosterone system as concomitant medication, whereas non-HF T2DM patients were optionally treated with SGLT2 inhibitor and ACEIs/ARBs/ARNI were prescribed in 26 individuals (86.7%). The gene discussed is REN; the disease is hydrops fetalis.